Despite the fact that these large trials have produced disappointing results with docetaxel-based combined anti-VEGF therapies, the notion that reduction of hypoxia and improvement of functional vascularization could sensitize to a therapeutic regimen has been successfully suggested in prostate cancer. Here, VEGFA is linked to Familial prostate cancer.